Purdue Pharma’s signature OxyContin product notched billions in annual sales, fueled by sales-force expansion and booming demand for high-dose pills
Purdue Pharma LP’s bankruptcy filing this week punctuates a fall from its perch as one of the pharmaceutical industry’s most recognizable marketers of opioid pain pills. At its height, Purdue’s signature OxyContin product notched billions of dollars in annual sales, fueled in part by booming demand for high-dose pills.
Purdue made about 10% of pills containing oxycodone—the active ingredient in OxyContin—that were purchased by U.S. pharmacies from 2006 to 2012, according to a Wall Street Journal analysis of opioid sales data...
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Purdue Pharma began cutting its opioid sales force last year, attorney says in bankruptcy hearingCNN News, delivered. Select from our newsletters below and enter your email to subscribe.
Consulte Mais informação »
Purdue Pharma will pay multibillion-dollar opioid settlement by selling more opioidsSome critics refer to such payments are being made with ‘blood money.’
Consulte Mais informação »
Purdue Pharma seeks to halt opioid suits against company, SacklersOxyContin maker Purdue Pharma LP on Wednesday asked a U.S. bankruptcy judge to h...
Consulte Mais informação »
Purdue Pharma seeks to halt opioid suits against company, SacklersOxyContin maker Purdue Pharma LP on Wednesday asked a U.S. bankruptcy judge to h...
Consulte Mais informação »
Purdue Pharma began cutting its opioid sales force last year, attorney says in bankruptcy hearingCNN News, delivered. Select from our newsletters below and enter your email to subscribe.
Consulte Mais informação »
Purdue Pharma will pay multibillion-dollar opioid settlement by selling more opioidsSome critics refer to such payments are being made with ‘blood money.’
Consulte Mais informação »